HIGHLIGHTS
SUMMARY
Few available data indicate that a mutation-based "neoadjuvant" therapy in advanced anaplastic thyroid carcinoma (ATC) might convert an initially unresectable primary tumor to resectable and optimize local tumor control. The authors evaluated a preoperative short-term "neoadjuvant" therapy with a BRAF-directed therapy or, in case of BRAF non-mutated tumors, an mKI/checkpoint inhibitor combination in three patients with ATC stage IVB and C. Methods In case of a BRAF-mutated ATC, a combination therapy of dabrafenib and trametinib, in case of BRAFwildtype ATC a combination of pembrolizumab and lenvatinib was given . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.